MATRX markets a number of pre-approved, drug products employing its SĀPH™ technology for controlled delivery.
SĀPH technology offers several advantages over current drug delivery products for new or approved generic medicines, including the delivery of small or large molecules (biologics, and drugs), hydrophobic or hydrophilic compounds, maintaining long-term residence at the target site, minimizing side effects due to improved localization, and providing sustained delivery options avoiding the need for repeated administration.
A summary of therapeutic focus areas and product pipeline is provided below.
Drugs embedded in Matrx’s SĀPH platform for delivery are typically approved through FDA’s ANDA approval path.
|DoxoSĀPH||solid tumor therapy||solid tumors|
|TaxoSĀPH||solid tumor therapy||solid tumors|
|cPtSĀPH||solid tumor therapy||solid tumors|
|OURS-MTZ||antibacterial||local – VE|
|OURS-MC||antifungal||local – VE|
|OURS-ABF||antibacterial + antifungal||local – VE|
|OURS-ABF+||antibacterial + antifungal + probiotic||local – VE|
|OURS-CT||non-hormonal contraceptive||local – VE|
|OURS-FR||vaginal freshener||local – VE|
|OURS-FR+||vaginal freshener + probiotic||local – VE|
|OURS-ES||vaginal atrophy||local – VE|
|GelClear-BB||glaucoma – β-blocker||local – ocular|
|GelClear-CAI||glaucoma – CAI||local – ocular|
|GelClear-BC||glaucoma – β-blocker + CAI||local – ocular|
|GelClear-MD||macular degeneration||retina – intraocular|
Abbr: CAI = carbonic anhydrase inhibitor; ES = estridiol; MC= miconazole; MTZ = metronidazole; IM =intramuscular; VE = vaginal epithelium